Search

Displaying results 3541 - 3550 of 6076 in total
  1. Drug

    MK-0557

    go.drugbank.com/drugs/DB12168
    Investigational

    MK0557 has been investigated for the treatment of Schizophrenia and Paranoid Schizophrenia.

  2. Drug

    BMS-863233

    go.drugbank.com/drugs/DB12357
    Investigational

    BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.

  3. Drug

    Oglemilast

    go.drugbank.com/drugs/DB12375
    Investigational

    Oglemilast has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.

  4. Drug

    Lisofylline

    go.drugbank.com/drugs/DB12406
    Investigational

    Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.

  5. Drug

    Methyl pyrrolidone

    go.drugbank.com/drugs/DB12521
    Investigational

    N Methyl Pyrrolidone is under investigation for the treatment of Multiple Myeloma.

  6. Drug

    GSK-1292263

    go.drugbank.com/drugs/DB12627
    Investigational

    GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

  7. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for

  8. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  9. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    Vitex agnus-castus fruit extract is obtained from dry fruits of Vitex agnus-castus. The fruits contain mixture of iridoids, flavonoids and compounds in leaves and flowers that structurally resemble sex hormones. Clinical studies demonstr...

    Mixtures: Menopause Relief for Women
  10. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.